Physician profile
Charles D Devine
NPI 1881687663
$131,407.98
in general payments reported to CMS, 2019-2025
20 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $25K · 2021: $25K · 2022: $2,310 · 2023: $880 · 2024: $2,468 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,889 · Education: $54.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,888.87 |
| Education | $54.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $64,107.71 | 2019-2021 | |
| Allergan, INC. | $28,661.46 | 2019-2021 | |
| Abbvie INC. | $22,933.86 | 2021-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $6,471.21 | 2019-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $4,686.20 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,173.82 | 2023-2025 | Caplyta |
| Neuronetics, INC. | $813.98 | 2019-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $508.31 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $483.07 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $336.99 | 2024-2025 | Rexulti |
| Corium, LLC | $327.41 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $283.68 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $162.33 | 2021 | |
| Vanda Pharmaceuticals INC. | $124.20 | 2025 | Fanapt |
| Tris Pharma INC | $89.79 | 2023-2025 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $66.24 | 2019 | |
| Tempus Ai, INC | $56.37 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $46.42 | 2024 | Cobenfy |
| Neos Therapeutics, Lp | $44.60 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $30.33 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.